Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Inclusion Criteria: * Children aged 6 months to 35 months * Those who was born after normal pregnancy period(37 weeks) for aged 6 months to \< 1 year * Those whose legally acceptable representative have given written consent to participate in the study and comply with all study requirements. Exclusion Criteria: * Subjects with immune deficiency disorder or malignant cancer. * History of any hypersensitivity following administration of vaccine or Guillain-Barre syndrome. * Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. * Subjects who experienced fever within 72 hours before vaccination or with the febrile disease(exceeding 38.0℃) on screening day. * Subjects who had received immunosuppressant or immune-modifying drug within 3 months before screening. * Subjects who had received blood products or immunoglobulin within 3 months before screening. * Subjects who had received influenza vaccination within 6 months prior to the screening. * Subjects who had received other vaccination within a month before screening, or those who had another vaccination scheduled within a month after study vaccination. * Subjects who had received any other investigational products within 4 weeks prior to study vaccination. * Subjects with clinically significant chronic disease. * Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.